Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT04838171
Recruiting Observational

Prospective Study of White Blood Cells

NCT04838171 · tracked via the Priya Life Science UK tracker
Sponsor
Quell Therapeutics Limited
Phase
Observational
Started
2021-03-24
Last updated
2026-01-21

Condition(s) studied

Autoimmune DiseasesInflammationRejection; Transplant, Liver

Investigational drug(s) / intervention(s)

White blood cell and blood collection

White blood cell and blood collection: Mononucleocytes will be collected via apheresis

Study summary

The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.

Primary outcome measure(s)

  • WBC characterisation to support the development of engineered regulatory T cells. — 5 years
    number, type and function of white blood cells in healthy controls and in patients

Trial sites (1)

FacilityCityRegionStatus
Quell Investigator Site 01 London United Kingdom Recruiting

More Quell Therapeutics Limited trials in the UK

Controlling Hyperactive Immunity With Long-lived Lymphocytes Recruiting
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients Active, not recruiting

Other trials for the same condition

Focused Orticumab Research for Treating Inflammation in Coronary Arteries Recruiting
Collection of Blood Samples for New Diagnostic Devices 2 Recruiting
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients Active, not recruiting
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04838171 on ClinicalTrials.gov ↗ ← All trials in the UK